Italia markets closed

Dow Jones
39.823,74
+16,97(+0,04%)
Nasdaq
16.798,24
+3,37(+0,02%)
Nikkei 225
38.946,93
-122,75(-0,31%)
EUR/USD
1,0857
-0,0005(-0,04%)
Bitcoin EUR
64.473,96
+2.115,34(+3,39%)
CMC Crypto 200
1.526,40
+37,86(+2,55%)

NVCR Dec 2025 15.000 put

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

5,90

0,00

(0,00%)

In data: 03:46PM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in